QED Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 Federal St, San Francisco, California...Phone Number
(650) 231-4088Website
www.qedtx.comRevenue
<$5 MillionIndustry
About QED Therapeutics
QED Therapeutics specializes in developing treatments for skeletal dysplasias, including achondroplasia and hypochondroplasia. The company is dedicated to research and has been involved in clinical trials, such as the breakthrough therapy designation by the FDA for its investigational drug infigratinib. Their target clients include healthcare professionals and individuals affected by these conditions, providing resources and advocacy support. As an affiliate of BridgeBio, QED Therapeutics aims to enhance the quality of life for those with skeletal dysplasias through innovative therapies and community engagement.Explore more
QED Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to QED Therapeutics
Compare insights from companies similar to QED Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
QED Therapeutics Tech Stack
A closer look at the technologies used by QED Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding QED Therapeutics
Sign Up For FreeTo access detailed company insights
QED Therapeutics specializes in developing treatments for skeletal dysplasias, including achondroplasia and hypochondroplasia. The company is dedicated to research and has been involved in clinical trials, such as the breakthrough therapy designation by the FDA for its investigational drug infigratinib. Their target clients include healthcare profe... Read More
